**Supplementary Fig. 8. Forest plot of adverse events with SOF/VEL±RBV-based DAA treatment of patients with decompensated hepatitis C cirrhosis.** AE 64.2% (95% CI: 34-89.4). SOF, sofosbuvir; VEL, velpatasvir; RBV, ribavirin; AE, adverse events.

